Evaluating Diagnostic Tests: Introducing a New Feature in AFP
Am Fam Physician. 2019 Jul 1;100(1):8.
Since 2003, American Family Physician (AFP) has published an ongoing series of short articles that systematically evaluate the attributes of new drugs using the STEPS (Safety, Tolerability, Effectiveness, Price, and Simplicity) framework.1 Choosing an appropriate treatment is only half of the challenge, of course; first, physicians need to make the correct diagnosis. Diagnostic test selection and interpretation are essential skills in family medicine.
Elements of the diagnostic testing process include estimating the pretest probability of disease based on the history, physical examination, and disease prevalence; selecting a test that best balances accuracy with potential harms and costs; and calculating posttest probability based on the test result.2 Other important factors to consider include test availability and how a test compares with alternative diagnostic strategies. Most importantly, we want to know whether performing a diagnostic test is likely to change patient management and improve patient-oriented outcomes.3,4
Unfortunately, many tests are promoted and disseminated into practice without a thorough assessment of their benefits and harms, which can include false positives, overdiagnosis, excessive cost, and overtreatment. For example, recently marketed tests that may cause more harm than good include immunosignature for cancer and infections; a breath test for lung cancer; patch vital sign monitoring; and biomarkers for Alzheimer disease.5
In this issue of AFP, we introduce the new feature “Diagnostic Tests: What Physicians Need to Know,” with a review of a blood test for colorectal cancer screening.6 Similar to “STEPS: New Drug Reviews,” this feature uses a structured approach to review key test characteristics, including discussions of accuracy, benefits, harms, cost, and cost-effectiveness. It concludes with a clinical bottom line: Is there a role for this test in primary care practice and, if so, for which patients? We aim for this new feature to cut through the “hype” and provide independent, objective assessments of new diagnostic tests that readers are considering incorporating into their practices. If you have comments about this feature or want to recommend new tests for us to cover, please let us know at email@example.com.
Editor's Note: Dr. Lin is Deputy Editor and Dr. Ebell is Deputy Editor for Evidence-Based Medicine for AFP.
Referencesshow all references
1. Shaughnessy AF. STEPS drug updates. Am Fam Physician. 2003;68(12):2342–2348....
2. Ebell MH. Diagnosis: making the best use of medical data. Am Fam Physician. 2009;79(6):478–480.
3. Fryback DG, Thornbury JR. The efficacy of diagnostic imaging. Med Decis Making. 1991;11(2):88–94.
4. Ferrante di Ruffano L, Hyde CJ, McCaffery KJ, Bossuyt PM, Deeks JJ. Assessing the value of diagnostic tests: a framework for designing and evaluating trials. BMJ. 2012;344:e686.
5. Hofmann B, Welch HG. New diagnostic tests: more harm than good. BMJ. 2017;358:j3314.
6. Lin KW. mSEPT9 blood test (Epi ProColon) for colorectal cancer screening. Am Fam Physician. 2019;100(1):10–11.
Copyright © 2019 by the American Academy of Family Physicians.
This content is owned by the AAFP. A person viewing it online may make one printout of the material and may use that printout only for his or her personal, non-commercial reference. This material may not otherwise be downloaded, copied, printed, stored, transmitted or reproduced in any medium, whether now known or later invented, except as authorized in writing by the AAFP. Contact firstname.lastname@example.org for copyright questions and/or permission requests.
Want to use this article elsewhere? Get Permissions